The Latest Breaking News from Vaccine

Mutated new Covid variant Pirola has seen cases spike, with government announcing the autumn vaccine programme will be brought forward

Biotech company Moderna (MRNA) recently published positive data from its latest flu vaccine trial, garnering investors’ attention. While the company focusing on expanding its product portfolio, is this the right time to invest in its stock? Keep reading.

Chlamydia is a major threat to koala populations across Australia. This bacterial disease infects between 20% and 90% of individuals in koala populations. It’s a major cause of the rapid decline of many wild populations, particularly in South-East Queensland and northern New South Wales.

All Americans ages 6 months and older are eligible for the new jabs, the CDC said Tuesday.

Pirro previously said Biden administration vaccine outreach programs were secret schemes to confiscate guns

Join Reason on YouTube and Facebook at 1 p.m. Eastern this Thursday for a discussion with Aaron Kheriaty, author of The New Abnormal about the persistent COVID mandates for K-12 schools, college campuses and health care settings.

The stock market held onto modest gains following CPI data. Shares of J.B. Hunt Transport Services rallied after its president gave encouraging words.

It could be the end of the needle for vaccines after COVID forced scientists to come up with alternatives. 

Moderna plans on investing $25 billion in research and development from 2024 through 2028.

Moderna said Wednesday its flu shot outperformed broadly used vaccines from Sanofi and GSK. The results bolstered Moderna stock.

Updated versions of the mRNA vaccines roll out this week. Experts say they offer good protection against current COVID variants. Who should get them, and when's the best time to roll up your sleeve?